LA
AEON icon

Linden Advisors’s AEON Biopharma AEON Stock Holding History

Linden Advisors’s Portfolio AEON Stock Details AEON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-518
Closed -$375K – 468
2022
Q4 		$375K Hold
518
– – ﹤0.01% 357
2022
Q3 		$368K Hold
518
– – ﹤0.01% 447
2022
Q2 		$367K Sell
518
-7,815
-94% -$5.51M ﹤0.01% 478
2022
Q1 		$5.87M Hold
8,333
– – 0.04% 301
2021
Q4 		$5.83M Hold
8,333
– – 0.04% 270
2021
Q3 		$5.85M Hold
8,333
– – 0.03% 280
2021
Q2 		$5.78M Buy
+8,333
New +$5.83M 0.03% 304

Other funds holding AEON

SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
FTCM
Fir Tree Capital Management New York $21.8M AUM 1.61% 1-Year Est. Return
ECP
Empyrean Capital Partners Los Angeles, California $3.07B AUM 34.24% 1-Year Est. Return
TCM
Tenor Capital Management New York $6.49B AUM 3.01% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
SIM
Sandia Investment Management Boston, Massachusetts $40.1M AUM 14.58% 1-Year Est. Return
CCA
Castle Creek Arbitrage Avon, Colorado $425M AUM 7.4% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return
GCWM
Graham Capital Wealth Management Washington D.c., District of Columbia $113M AUM 11.26% 1-Year Est. Return

Linden Advisors's AEON Position: Q1 2023 in Review

Linden Advisors sold out of AEON Biopharma (AEON) in Q1 2023, closing a stake of 518 shares — an estimated $375K sold.

Linden Advisors first reported a position in AEON in Q2 2021 and held it in 7 quarters. The position peaked at $5.87M in Q1 2022. 21 funds tracked by Wall St. Rank hold AEON as of Q1 2023.

  • Linden Advisors reported no remaining AEON Biopharma position as of Q1 2023 after selling out during the quarter.
  • Linden Advisors sold 518 AEON Biopharma shares in Q1 2023, an estimated $375K.
  • Linden Advisors first reported a position in AEON Biopharma in Q2 2021 and held it in 7 quarters.
  • Linden Advisors's AEON Biopharma position peaked at $5.87M in Q1 2022.
  • 21 funds tracked by Wall St. Rank held AEON Biopharma as of Q1 2023.

Based on Linden Advisors's 13F filing for Q1 2023, filed 15 May 2023.